Key result
Double RAS blockade lowers blood pressure more than monotherapy despite inconsistent long-term outcome benefits.
Why the study?
Does double renin-angiotensin system blockade improve clinical outcomes compared to monotherapy?
Comparison
Double renin-angiotensin system blockade vs Monotherapy with a single RAS blocking agent
Design
Review
Authors
Loading...
Greater BP reduction with dual RAS blockade does not consistently improve outcomes and may raise renal risks; leaves open its role versus monotherapy.
Does double renin-angiotensin system blockade improve clinical outcomes compared to monotherapy?
While double RAS blockade lowers blood pressure more effectively than monotherapy, its clinical outcome benefits vary by population and it may increase the risk of adverse renal events.
Haralambos Gavras (2008) conducted an editorial in Hypertension and end-organ damage. Double Renin-Angiotensin System Blockade vs. Monotherapy was evaluated. Double blockade of the renin-angiotensin system using combinations of ACE inhibitors, ARBs, or renin inhibitors achieves greater blood pressure lowering than monotherapy, though long-term outcome benefits remain inconsistent.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: